BerandaA1LN34 • BVMF
add
Alnylam Pharmaceuticals Inc Bdr
Tutup sebelumnya
R$71,74
Rentang tahun
R$36,23 - R$85,44
Kapitalisasi pasar
31,35 M USD
Volume Rata-Rata
38,00
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 593,17 jt | 34,90% |
Biaya operasional | 595,51 jt | 26,63% |
Laba bersih | -83,76 jt | 39,24% |
Margin laba bersih | -14,12 | 54,96% |
Penghasilan per saham | 0,06 | 107,79% |
EBITDA | -90,99 jt | 11,59% |
Tarif pajak efektif | 56,81% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,69 M | 10,46% |
Total aset | 4,24 M | 10,71% |
Total liabilitas | 4,17 M | 3,02% |
Total ekuitas | 67,09 jt | — |
Saham yang beredar | 129,46 jt | — |
Harga terhadap nilai buku | 137,96 | — |
Tingkat pengembalian aset | -6,23% | — |
Tingkat pengembalian modal | -9,44% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2024info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -83,76 jt | 39,24% |
Kas dari operasi | -94,66 jt | -217,71% |
Kas dari investasi | -52,91 jt | 78,01% |
Kas dari pembiayaan | 31,00 jt | -20,98% |
Perubahan kas bersih | -133,85 jt | 39,25% |
Arus kas bebas | -110,30 jt | -165,23% |
Tentang
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Didirikan
14 Jun 2002
Situs
Karyawan
2.230
